Skip to content

Pilar A. Sáiz

6 papers in the library · 72 citations · publishing 2002-2025

Papers

Sort Most recent Most cited

Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects

Frontiers in Psychiatry August 4, 2025 Fernando Mora, J. Ramos-Quiroga, Enrique Baca-García et al. 5 citations

Introduction Depression is a highly prevalent disease that severely impacts the life of patients. Inadequate response to at least two antidepressants despite adequacy of treatment and adherence is known as treatment-resistant depression (TRD), which entails a higher social and economic burden than non-resistant major depression. The lack of consensus on the definition of TRD and other aspects...

A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study.

Advances in Therapy May 1, 2025 Patricio Molero, Angela Ibañez, Javier de Diego-Adeliño et al. 8 citations

The INTEGRATE study aimed to provide information on the use, effectiveness, and safety of esketamine nasal spray (ESK-NS) for the treatment of treatment-resistant depression (TRD) in real-world practice in Spain. This was an observational, cross-sectional, retrospective study conducted in adults aged 18-74 years who met the criteria for TRD. The weekly impact of ESK-NS on depressive symptoms...

Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

Schizophrenia Bulletin July 2, 2019 Laura Ferraro, Caterina la Cascia, Diego Quattrone et al. 25 citations

Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6...

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

The Lancet Psychiatry May 1, 2019 Marta Di Forti, Diego Quattrone, Tom P. Freeman et al.

Summary Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder....

History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders

European Addiction Research March 21, 2019 I. Menéndez-Miranda, Leticia García-Álvarez, M. García-Portilla et al.

Background: Data on associations between cannabis use and psychopathology, cognition and functional impairment in schizophrenia spectrum disorders (SSD) is controversial. Objectives: To examine the effect of cannabis on psychopathology, cognition and real-world functioning in SSD patients. Method: Naturalistic cross-sectional study, 123 clinically stable SSD outpatients. Assessment: demographic...

Use of MDMA and Other Illicit Drugs by Young Adult Males in Northern Spain

European Addiction Research 2002 Julio Bobes, Pilar A. Sáiz, María Paz García‐portilla et al. 34 citations

<i>Aim: </i>To measure the prevalence of 3,4-methylenedioxymethamphetamine (MDMA) and other drug use in young males entering compulsory military service in Asturias (northern Spain) and to define trends in MDMA use in this group during the period from 1995 to 1999. We also sought to determine whether MDMA users have distinct personality features or higher levels of sensation seeking....